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Andreas M Svennebring* and Jarl ES WikbergAbstract
Three dedicated approaches to the calculation of the risk-adjusted net present value (rNPV) in drug discovery
projects under different assumptions are suggested. The probability of finding a candidate drug suitable for clinical
development and the time to the initiation of the clinical development is assumed to be flexible in contrast to the
previously used models. The rNPV of the post-discovery cash flows is calculated as the probability weighted average
of the rNPV at each potential time of initiation of clinical development. Practical considerations how to set
probability rates, in particular during the initiation and termination of a project is discussed.
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Risk-adjusted net present value, rNPVBackground
Drug discovery and development programs offer particu-
lar difficulties in the estimation of profitability, largely
due to their high attrition rates, but they also offer
opportunities to handle the problem because of the well-
defined phases of the process. Drug discovery and devel-
opment programs constitute a special case of investment
under ongoing uncertainty (Dixit and Pindyck 1994;
Schwartz and Trigeorgis 2004). The current main ap-
proach for evaluation is modifications of the classical net
present value concept; in particular, the risk-adjusted net
present value (rNPV) method is commonly employed,





1þ rð Þt nð ÞRn
; ð1Þ
where Cn is the n
th cash flow of N in total, R0 and Rn is
the estimated probability of obtaining the entire series of
cash flows from the initiation of the project and from
the nth cash flow, respectively, r is the discount rate and
t(n) the time of the nth cash flow (Stewart 2002; Stewart
et al. 2001). Presentations and demonstrations of the im-
plementation of the rNPV calculation in drug develop-
ment projects found in literature generally start only
right at the initiation of the phase I clinical trial, in the
discovery and development pipeline. The complexity of* Correspondence: andreas@svennebring.com
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reproduction in any medium, provided the origthe drug discovery, the high costs for producing suitable
data, and the limited access to such information for ac-
tors outside organizations undertaking discovery activ-
ities, it may seem difficult to model the cost of the drug
discovery process. In projects requiring major econom-
ical investments such as the construction of a building,
bridge, oil platform or the clinical development of a
drug, the time required for each development step is un-
certain. While a clinical phase III trial usually takes 3–5
years, the average of 4 years may be a good estimate for
the rNPV approach. However, in drug discovery en-
deavors, the time from initiation of the project to the
generation of the first candidate drug ready for clinical
development may vary from a few years and up without
any distinct upper limit or guarantee that a compound
ever will be found.
Nevertheless, in view of the high risk involved and the
constant decline in productivity among the industry, the
financial aspects of drug discovery endeavors, rNPV
extensions tailored for the evaluation of drug discovery
projects are urgently needed. Herein, a few approaches
valid under different assumptions are suggested and
discussed.Model framework
We assume that the total risk-adjusted net present value
(rNPVtot.) of the expected cash flows resulting from a
drug discovery endeavor is the value of the cash flows
during the discovery phase (rNPVD) and the real value
of the cash flows post-discovery (rNPVPD), hence:inger. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Figure 1 Probability tree diagram showing possible scenarios
for finding a compound fit for development with their
associated probabilities indicated above and under the arrows.
The probability expressions are not cumulative. During the first
period, the probability of generating a candidate drug is p, while the
probability of not generating one is 1-p. If no drug is discovered
during the first interval, a new chance is given during a second
interval, which also has a probability of p for success. If no candidate
drug is found during the first two periods, a last chance is given
during the third interval.
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The problem with the valuation of the post-discovery
phase is that the time of its initiation is unknown, if even
it is ever to arrive. To simplify handling the valuation of
the post discovery cash flows, we define the time de-
pendant post-discovery net present value (rNPVPD, t) as
the rNPV that we would face assuming that the develop-
ment was initiated at time t. We also define the current
post-discovery net present value (rNPVPD, 0) as the rNPV
of the post-discovery cash flows assuming that the devel-
opment start at present time, i.e. when the phase I clin-
ical trial is just about to begin. In the methods described
here, it is assumed that the valuation of the post-
discovery cash flows is done as a separate entity through
the rNPV method. The rNPVPD, t can thus be calculated
at a specific time (t) from the rNPVPD, 0:
rNPVPD;t ¼ rNPVPD;0
1þ rð Þt : ð3Þ
The rNPVD is calculated as the sum of the products
between the probability that a scenario (the nth scenario)






1þ rð Þt nð Þ
: ð4Þ
In the same vein, the rNPVPD. is calculated as the sum
of the products between the probability that the nth sce-





pn⋅rNPVPD;t nð Þ: ð5Þ
New model suggestions
Instead of dividing the discovery phase in parts, the
process is seen as a black box generating compounds
ready for clinical development with a certain probability.
The planned time cause of the discovery process is di-
vided in periods of constant length, which is set on a
pragmatic basis, and the project continuous for N time
periods. The chance of finding a compound ready for
clinical development is either constant (p) or different
(pn) between the different time periods.
The ability of a research organization to generate com-
pounds fit for clinical development must be highly re-
lated to the economic resources allocated to the
organization. We therefore assume that under the use of
a fixed set of technologies the probability (pn) of finding a
compound as the result of an investment is proportionalto the product of the cash flow allocated to discovery re-
search activities at the time interval and a constant (P) de-
noting the probability of finding a compound per
monetary unit:
pn ¼ CnP; ð6Þ
where Cn denotes the cash flow to discovery activities at
the nth interval.
In many drug discovery projects, the synthesis and
early ADMET (absorbtion, distribution, metabolism,
elimination and toxicology) investigations are done by
contract research organizations (CROs). When a com-
pound suited for clinical developments has been found
the entire focus may swiftly shift to the clinical phase.
Our first model is based on the assumption that a drug
discovery project is run until a suitable candidate for
clinical development has been found, at which time
point the discovery activities cease and the clinical devel-
opment is initiated. The project goes on for a finite
period of time of totally N periods.
In our first model (Figure 1) we further assume that
the probability of finding a compound for development
is constant during the entire discovery period as a result
of a fairly constant cash flow to the research activities
over time. During the first time period, the probability of
finding a candidate drug is p. If no candidate is found
during this period, the cumulative probability of finding
a candidate in the second period is consequently (1-p)p,
in the third it is (1-p)2p, and after n time periods it is (1-
p)n-1p. The effective rNPV experienced if a candidate
drug is discovered during time period n is therefore
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p 1 pð Þn1⋅ Cn
1þ rð Þn tð Þ
 !
: ð8Þ
In cases where the cash flow to the discovery activities
is changing considerably over time, it might be necessary
to use different probability rates at different time inter-
vals. In our second model (Figure 2), we assume that the
probability of finding a candidate drug for further devel-
opment is pn for the n
th period. During the first period,
the probability of finding a candidate drug for develop-
ment is thus p1, during the second period it is p2, lead-
ing to a cumulative probability at t = 0 of (1-p1)p2, and
accordingly at the third interval to (1-p1)(1-p2)p3. The
cumulative probability of finding a candidate at the nth





From this expression we can calculate the rNPVPD as
the sum of the probability that the development will be
initiated in each possible time point multiplied with the









⋅rNPVPD;t nð Þ; ð10ÞFigure 2 Probability tree diagram showing the possible
scenarios in a drug discovery project conveying to Figure 1,
where the probabilities for success are different for the











1þ rð Þn tð Þ
: ð11Þ
In our third model, we assume that more than one
compound may be selected for clinical development. We
also assume that the project continues even in the event
that a candidate compound is found. If a large number
of compounds are prepared and the probability that one
of the compounds will be suitable as a drug is p, the
chance of finding two compounds during the same time
period is p2, and the chance of finding three is p3. The
probability of finding m compounds for further develop-
ment at one time interval is thus pm. The model is
designed particularly for application in projects where
the probability of finding compounds for development is
high enough to make it probable to find more than one
suitable compound for development during the same
time period, and where it is judged meaningful to initiate
the clinical development with multiple compounds.
Apparently, there is a limit how many compounds that
can be prepared in a project and consequently how
many compounds that can be found for further develop-
ment. Strictly speaking, if A compounds are prepared in
a project, the probability of finding a second compound
for development would be p(A-1)/A, the third com-
pound p(A-2)/A, and so on. However, due to the ex-
tremely large number of compounds theoretically
possible to prepare in a drug discovery endeavor, we as-
sume that the probability of finding additional com-
pounds for development is equally high. Since the
probability of finding multiple compounds quickly de-
creases with increasing exponent, we suggest that no
upper limit is set for how many compounds that may be
found fit for development in order to render a generally
accepted expression. Under these assumptions, the aver-
age amount of compounds under development equals




The rNPV of one time interval equals the average
amount of compounds for development for the interval





and for the entire time period during which discovery
activities are planned spanning N time intervals, the
rNPVPD and rNPVD equals:
Table 1 The probability of finding a drug in year 1–5
according to model 1 and 3
Cash-flow to discovery/year (million $)
n 0,5 1 3
Model 1 1 0,0350 0,0700 0,2100
2 0,0338 0,0651 0,1659
3 0,0326 0,0605 0,1311
4 0,0315 0,0563 0,1035
5 0,0304 0,0524 0,0818
Model 3 All 0,0376 0,0809 0,3365
A probability rate P of 7 10-8 compounds/$ and a constant cash-flow to the
discovery activities of $0.5 m, $1 m and $3 m per year has been used. In
model 3, the probability weighted amount of drugs that may be found.
Figure 3 The probability of finding a drug in year 1–5 with a
probability rate P of 7 10-8 compounds/$ and a constant cash-
flow to the discovery activities of $0.5 m (empty bar), $1 m
(gray bar) and $3 m (black bar) according to model 1.























We wish to demonstrate the utility of the model from
a few simple calculations in which rough estimates of
the parameters have been deduced from publicly avail-
able data. It has been estimated that the discovery phase
account for approximately 30% of the total discovery
and development cost of a drug, which may be around
$1b making $300 m a rough estimate of the outgoing
cash-flow necessary for the discovery of a drug including
failing compounds (DiMasi et al. 2003). Of the drugs en-
tering into phase I trials, approximately 5% later reach
approval by regulatory authorities (Arrowsmith 2012).
The cost per compound entering clinical development is
thus $15 m and P = 1/$15 m approximating 7 10-8 com-
pounds/$.
Assume a drug discovery project which has reached a
level of maturity with compounds in all different stages
of preclinical development and where the same cash-
flow is fed to the discovery activities each year. Under
the assumptions in model 1 (and 2), the probability of
finding the only compound to proceed with into clinical
development during one particular year from start
equals p(1-p)n-1. In contrast, the number of compounds
for clinical development weighted with the probability of
occurrence does not change over the years as apparent
in equation 9. The probability of finding one compound
(model 1) or the expected amount of compounds
weighted against the probability (model 3) has been cal-
culated for the project described in which an annualcash-flow to the discovery work is $0.5 m, $1 m or $3 m
per year, respectively (Table 1). The data from model 1
has been graphically displayed in Figure 3.
In model 1 with a cash-flow of $0.5 m/year, the chance
of finding a compound is 3.5% and falling slightly over
the coming years due to the chance that a compound
has been found during the previous years and the dis-
covery work will be discontinued. The decrease becomes
higher with increasing annual allocation and with a
cash-flow of $3 m/year, it is after four years half of the
probability of the first year. While using model 3, the
probability weighted amount of compounds found with
an annual investment of $0.5 m is only slightly higher
than what was found for model 1, an increase that is
due to the fact that in model 1 only one compound can
be found, but more than one in model 3. However, the
probability of finding two compounds suitable for devel-
opment with this limited budget is very low. With in-
creasing annual allocations, the probability of finding a
second compound starts to affect the probability rate
considerably.Results and discussion
Mathematical models are fabrications designed to cap-
ture the most essential aspects of reality. It is therefore
imperative to acknowledge all imperfections to the models
and to the degree it is possible to account for them in the
process of setting the parameters (i.e. parameter estimates)
fed to the model or to craft the models. The probability of
finding a compound fit for development is likely to change
from the beginning of a project and onwards due to ex-
perience, and a considerable lag time must be expected
between cash flows to the project and the probability that
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sult of the investment.
The process of drug discovery can be divided into
steps and functions in slightly different ways (Ashburn
and Thor 2004; Pritchard et al. 2003; Schirle et al. 2012).
We prefer to present the process without being too de-
tailed in the description about what exact tasks and
functions are done in each step since these often overlap
in time, and we assume that the target identification and
validation step is already finished at the onset of the dis-
covery phase. The initiation of a drug discovery project
is usually preceded with the identification of a target,
such as a receptor protein; the function of which is go-
ing to be manipulated with a new drug (Figure 4).
The first step in the discovery phase is generally
termed lead discovery and has the goal of identifying
novel compounds with a weak drug effect, serving as
starting points for further development. From the lead
structure, a structural core is identified and the substitu-
ents, i.e. the “decoration” of the core, is tailored to ren-
der an optimal structure with respect to target activity
and ADMET properties, This is a process known as lead
optimization. The optimized compounds are subjected
to a number of tests to investigate the faith of the com-
pounds in the human body and their ability to cause
toxic effects. These activities are often referred to as
ADMET and are often divided in an early and a late pre-
clinical phase, where the former primarily focuses on
in vitro tests, and the latter is primarily concerned with
animal tests. Today, the optimization process is usuallyFigure 4 Drug discovery starts after a target has been identified and
of the drug development activities. a. In the traditional Figure, the lead
the compounds, after which the early preclinical phase commences. b. Tod
activity but also on the early ADMET properties. The lead optimization and
course of the discovery pipeline, data is generated describing the ability of
for the identification of new compounds for synthesis that are more likely
for clinical drug usage.intertwined with the early ADMET, since both ADMET
qualities and drug activities are nowadays usually con-
comitantly concerned during the optimization process.
During the course of a project, considerable experience
is gained with time. With the synthesis of increasing
amounts of compounds, it is possible to describe the con-
nection between chemical structure and functional activity
at the target, so called structure-activity relationships
(SARs) that can guide the researchers into a more pros-
perous direction later in the project (Lewis 2005; Lin et al.
2006). Also for the ADMET properties, relationships be-
tween chemical structure and drug properties can be pre-
dicted based on previous experience (Ponec et al. 1999;
Shen et al. 2003). Specifically, the data produced from
physicochemical characterizations, biological in vitro as-
says and animal in vivo experiments on the accumulating
compounds synthesized during the course of a project are
used to create statistical mathematical models from which
the performance of not yet synthesized compounds can be
predicted (Figure 5) (Wikberg et al. 2011). With the
advent of the models, new improved compounds can be
hypothesized, synthesized and evaluated based on predic-
tions of the models. The process is now implemented on a
broad scale among the industry, under the name ’predict-
ive modeling. The ability to generate compounds for clin-
ical development is therefore likely to increase with time
during the project.
When the models presented herein are used practic-
ally, it must be considered that the resource allocation
between early and late activities in the discovery pipelineends with the initiation of clinical phase I, the later which is part
optimization process is focused on optimizing the functional activity of
ay, lead optimization usually focuses not only on optimizing functional
early preclinical steps are therefore fused into one step. c. During the
the synthesized compounds to function as drugs. The data is utilized
than the previously made to excerpt the prerequisites to be acceptable
Figure 5 The iterative refinement cycle through which
experience is utilized to increase the probability of success in
coming series of compounds. Compounds are synthesized in a
project and subjected to assays and animal tests, which generate
data that indicate the likelihood for a compound to be functional as
a drug. The data is used to create statistical mathematical models
that describe the connection between chemical structure and
expected behavior of the compounds. Such models may be
directed to compound activities on multiple targets, to ADME
properties and toxicity, and include approaches such as QSAR and
proteochemometric modeling. The models may be based on the
data developed within the project, as well as on public data and
data from earlier projects. The model are used to predict the
behavior of novel structures, based on which the most promising in
the next series to be synthesized will be based on. Over time the
models become more and more predictive when the process is
iterated, which will increase the likelihood of finding suited
compounds. The entire process is implemented on a broad
systematic scale among the industry under the name
‘predictive modeling’.
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founded and mature projects. Assume the life cycle from
foundation to termination of a drug discovery enterprise
based on only one single project, a so-called pure play
company. In the newly founded enterprise, not so many
compounds have qualified for preclinical investigations
yet. In many cases, the entire outgoing cash flow goes to
compound synthesis, i.e. discovery and optimization of
leads. Maybe the lead optimization process has not even
yet started. The probability of obtaining a compound fit
for clinical development must be practically null under
these circumstances. However, while the project or com-
pany matures, an increasing fraction of the research spend-
ing goes to preclinical activities. In this stage of maturity,
the prospect of generating compounds fit for clinical devel-
opment becomes considerable. When the drug discovery
pipeline is well-populated with compounds, all four phases
are cost drivers and the probability of generating a candi-
date drug is decent.
In view of the above discussion it is possible to utilize
management accounting information to adjust the prob-
ability rates in the models so that in every time interval
they reflect the probability of finding a compound fit for
clinical development as accurately as possible. For an in-
vestor, without access to this information, it may bepossible to use official reports for the same purpose. If a
project is just about to start, it might be rational to as-
sume that no compounds will be generated during the
first years, and that a certain starting time with a startup
cost should apply. It might also be meaningful to add a
delay to the probability time series so that the cash flows
during one time period reflect the probability of generat-
ing a candidate drug during a later period. The know-
ledge that a relatively large amount of the cash flows will
go to late preclinical development might give reason to
increase the calculated pis.
The question of how many compounds that are gener-
ated for clinical phase I trials is in reality not as straight-
forward as the models presented herein suggest. In drug
discovery projects, usually a large number of highly rem-
iniscent structures are synthesized, from which usually a
number of compounds can be identified as good candi-
dates for further development. However, only one or
maybe two of these are generally chosen for clinical de-
velopment. If a compound fails in clinical phase I, which
is usually due to toxicity or other adverse effects, it is
likely that other compounds with just minor changes to
the structure will share the same problems. It may there-
fore be misjudged to look at each individual compound
that could be considered for clinical development as a
hit in the models presented. Rather, a structurally more
distant molecule might be meaningful to take to the
clinic. In fact, there exist mathematical methods to
compute the chemical similarities of compounds, based
on which it would be possible to implement filters to
judge if a compound is truly ’novel’ in the sense of
bringing it into clinical development, compared with
previously failed compounds.
The models should therefore be regarded in instru-
mentalistic terms rather than as a reflection of how real-
ity works. How many compounds that are considered fit
for clinical development is dependent on how strict cri-
teria that we apply in the selection process. With very
liberal criteria, the probability of finding suitable com-
pounds must be set high, but the lower success rate in
the clinical development must be reflected in the param-
eters for probability in the clinical development.
At last we would like to mention that the practices for
economic evaluation of biotechnology pure play enter-
prises is currently poorly developed. In a report from the
management consulting firm McKinsey from 2000 based
on interviews with 44 CEOs and business developers
from representative pharmaceutical and biotechnology
companies found that one third admitted not to employ
any economically valid evaluation method. Among these,
21% used simple cost plus approaches and 12% simply
made a guess (Moscho et al. 2000). This study argued
that a reliable economic valuation is necessary in order
to persuade financiators to invest in the enterprice and
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is potentially deleterious for all parties when deals are
based on unrealistic expectations. It is also noteworthy
that the pharmaceutical industry is in a crisis with de-
clining productivity and increasing costs, which the
major companies seek to counteract by in licensing only
late projects in clinical development, shifting the major
risk to small enterprises and start-ups, while on the
other hand venture capital has become increasingly re-
luctant to fund the early projects. In an overall perspec-
tive these developments may not be cost-effective for the
sake of public, for which there is still a very large unmet
need for effective treatments of a large number of severe
and disabling diseases. The development of methods for
the rational evaluation of drug discovery is thus essential
for a wealthy drug discovery sector to develop, to which
end we hope that our proposed approaches will contribute.
Conclusions
We have suggested three dedicated extensions to the net
present value calculation for drug discovery projects.
The process of setting parameters for the models and
their overall utility has been discussed. We propose that
the models shall be considered in the evaluation of early
drug discovery endeavors for the future, and that their
practical implementation for the purpose is a highly de-
sired task to study.
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